Keywords: fda, starts, safety, review, roche, cellcept, novartis

FDA starts safety review of Roche's CellCept and Novartis' Myfortic after cases of PML

Article | 21 April 2008

Print This

The US Food and Drug Administration is investigating two organ transplant rejection drugs to establish whether they increase the risk ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in